Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/jdh5cp26

A COMPREHENSIVE REVIEW OF EMPAGLIFLOZIN AND TOPIRAMATE IN THERAPEUTICS, DRUG DEVELOPMENT AND ANALYTICAL SCIENCES

Shaily Joshi[1], Ms. Purvi Ramanuj[2*], Dr. Pragnesh Patani[3]

[1]Student, Khyati College of Pharmacy, Gujarat Technological University
[2*]Department of QA and Pharmaceutical Chemistry, Khyati College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.
[3]Department of Pharmacology, Khyati College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.

***Corresponding Author: Purvi Ramanuj**
*Khyati College of Pharmacy, Palodia, Ahmedabad *mail: purviramanuj01@gmail.com

Abstract
Empagliflozin, a selective sodium–glucose co-transporter 2 (SGLT2) inhibitor, and Topiramate, an antiepileptic drug with weight-reduction potential, have emerged as clinically important agents in diverse therapeutic areas. Empagliflozin has demonstrated efficacy in type 2 diabetes, cardiovascular protection, and chronic kidney disease, while Topiramate has utility in Obesity epilepsy, migraine prophylaxis, and psychiatric disorders. Recent studies highlight potential synergistic benefits in weight management when used in combination. This review comprehensively examines their pharmacology, drug development history, analytical methods, therapeutic applications, safety, and future perspectives. Analytical sciences have contributed robust HPLC and LC–MS/MS methods for Empagliflozin quantification, while validated methods like HPLC, LC–MS/MS, GC–MS, CE, HPTLC, and spectrophotometry also exist for Topiramate. This article integrates advances across therapeutics, regulatory development, and analytical sciences to provide a holistic understanding of these two agents.

Keywords: Empagliflozin, SGLT2 inhibitors, Topiramate, Obesity, Heart Failure, Migraine, Epilepsy, Analytical methods, HPLC, LC–MS/MS, UV-Spectrophotometric, RP-HPLC, HPTLC, SI-HPTLC.

1. Introduction

The past two decades have witnessed significant advances in metabolic and neurological therapeutics, with two agents Empagliflozin (EE) and Topiramate (TPM) emerging as paradigmatic examples of translational drug discovery and repurposing.

For the treatment of type 2 diabetic mellitus (T2DM), empagliflozin (EE), a highly selective C-aryl glucoside sodium–glucose cotransporter-2 (SGLT2) inhibitor, was initially authorized in 2014. EE causes natriuresis and glycosuria without the need for insulin by preventing glucose reabsorption in the renal proximal tubule [1]. Beyond glycaemic management, EE provides clinically significant cardiovascular and renal protection across a variety of heart failure and chronic kidney disease phenotypes, according to landmark outcome trials [2–4].

On the other hand, topiramate (TPM) was developed as a broad-spectrum antiseizure and migraine preventive medicine after being accidentally found during the hunt for antidiabetic medications [5]. Its numerous mechanisms—which include carbonic anhydrase inhibition, excitatory neurotransmission inhibition, and GABAergic signaling enhancement—account for its therapeutic versatility in the treatment of epilepsy, migraine prevention, and weight control [6]. Crucially, its ability to reduce body weight paved the way for the creation of combination pharmacotherapy, which was a significant advancement in the treatment of obesity [7].

Novel co-therapy for obesity with EE and TPM has been investigated in recent translational trials, showing synergistic metabolic and weight-loss advantages [8,9]. With a critical focus on the new EE–TPM combination paradigm, this study compares the pharmacology and clinical data of EE and TPM, maps their drug development pipelines and intellectual property landscapes, and summarizes the current state of analytical methodologies.

2. Pharmacological Profile

2.1. Empagliflozin

Empagliflozin is a selective inhibitor of sodium–glucose co-transporter-2 (SGLT-2) that operates on the nephron's proximal renal tubules.

- **Renal Glucose Reabsorption Inhibition**: About 90% of filtered glucose is reabsorbed by the kidney through SGLT-2 under normal physiology. By blocking this transporter, empagliflozin decreases glucose reabsorption and increases glucose excretion in the urine [10].
- **Glucose-Lowering Effect**: This process lowers fasting and postprandial glucose levels by reducing plasma glucose levels without the need for insulin secretion [11].
- **Insulin-Independent Mechanism**: This process lowers fasting and postprandial glucose levels by reducing plasma glucose levels without the need for insulin secretion [12].
- **Cardio-Renal Benefits**: Osmotic diuresis and natriuresis are secondary mechanisms that result in decreased plasma volume, arterial stiffness, and afterload; furthermore, it has been suggested that ketone body metabolism is modulated and myocardial energetics are enhanced [13,14].

2.2. Topiramate

Topiramate is a broad-spectrum anticonvulsant with a multifactorial mechanism of action, contributing to its efficacy in epilepsy, migraine prophylaxis, neuronal membrane stabilization, anti-excitatory balance appetite/hedonic suppression contributing to weight loss.

- **Voltage-Gated Sodium Channel Blockade**: Topiramate stabilizes neuronal membranes and blocks voltage-dependent sodium channels to prevent prolonged repeated neuronal activation [15].
- **Enhancement of GABAergic Transmission**: It increases chloride influx and fosters inhibitory neurotransmission by favorably modifying GABA-A receptor activation [5].
- **Antagonism of Glutamatergic Transmission**: Topiramate reduces excitatory neurotransmission by specifically blocking AMPA/kainate subtype glutamate receptors [16].
- **Carbonic Anhydrase Inhibition**: It contributes to acid-base alterations and may have antiepileptic and weight-loss benefits due to its modest suppression of carbonic anhydrase isoenzymes II and IV [17].
- **Migraine and Weight Loss Mechanism**: GABAergic enhancement and glutamate antagonism are associated to appetite reduction in the treatment of obesity, while cortical spreading depression and trigeminovascular activation may be modulated in migraine prevention [18].

2.3. Empagliflozin - Topiramate Combination

Combining empagliflozin and topiramate may be therapeutically justified due to their complimentary actions, which target both neurological and metabolic processes. By specifically blocking renal SGLT-2 transporters, empagliflozin lowers plasma glucose, encourages the excretion of glucose through the urine, causes a slight decrease in body weight, and improves insulin sensitivity [10,14]. Originally created as an anticonvulsant, topiramate helps people lose weight and improve their

metabolism through a number of mechanisms, including weak inhibition of carbonic anhydrase isoenzymes, blockade of voltage-gated sodium channels, inhibition of AMPA/kainate glutamatergic signaling, and enhancement of GABAergic inhibitory neurotransmission. These mechanisms collectively lead to decreased appetite, altered energy balance, and better glycemic control [5,16,17]. When combined, Topiramate has a central neuro-metabolic effect by regulating appetite regulation and energy expenditure, while Empagliflozin offers a peripheral mechanism by boosting glucose clearance through glycosuria and natriuresis. By targeting both hyperglycemia and excess adiposity, this dual action may provide patients with obesity, type 2 diabetes, and metabolic syndrome with additive benefits that reduce cardiovascular and metabolic risk more effectively than either medication alone [19,20].

3. Therapeutics (Applications + Clinical Evidence)

A selective sodium–glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin is authorized for the treatment of type 2 diabetic mellitus (T2DM) and has also shown promise in protecting the kidneys and heart. In T2DM patients at high cardiovascular risk, landmark trials like the EMPA-REG OUTCOME study shown a significant decrease in cardiovascular mortality and heart failure hospitalization [1], However, the EMPEROR-Reduced and EMPEROR-Preserved investigations confirmed both renal and cardiac benefits by expanding its prescription to patients with heart failure over a wide range of ejection fractions [3,4]. Clinically licensed for the treatment of epilepsy and migraine prevention, topiramate is an anticonvulsant with pleiotropic effects on GABAergic transmission, glutamate inhibition, and carbonic anhydrase blocking [5,6,18]. Clinical research has further demonstrated its promise for weight control, with trials demonstrating notable weight loss and improvements in comorbidities associated with obesity when paired with low-dose phentermine [7,19,20]. Beyond their separate applications, new research backs up the therapeutic justification for empagliflozin and topiramate together, especially in the treatment of obesity and metabolic syndrome. Dual therapy dramatically improved anthropometric measurements, insulin sensitivity, and lipid markers in overweight or obese non-diabetic people undergoing calorie restriction, according to a new randomized clinical research [8]. Topiramate's appetite-suppressing and energy expenditure-boosting qualities combined with empagliflozin's glucuretic and cardiometabolic effects are thought to produce this synergistic effect, offering a novel pharmaceutical strategy to the treatment of obesity and metabolic disorders [8,9].

4. Drug Development Perspective

4.1. Formulation Challenges

The therapeutic efficiency of empagliflozin is hampered by its limited permeability and decreased oral absorption, despite its acceptable solubility profile [11]. Human research indicates that 75–77% of the chemical remains intact in plasma after oral administration, although its bioavailability varies greatly between species, with 94% in mice and 89% in dogs and just 31% in rats [21]. These discrepancies complicate formulation standardization and demand optimization of delivery systems. As a BCS Class III medication, topiramate has a low solubility (~8.3 mg/mL at 25 °C), which makes it difficult to create stable oral solutions, especially at therapeutically relevant dosages (~10 mg/mL). These solutions frequently call for extremely high pH values or poorly tolerated solvents, and they are vulnerable to physical instability such phase separation and precipitation [22].

4.2. Novel Delivery Systems

- **Empagliflozin Orodispersible Tablets (ODTs)**: Tablets disintegrated in 30 seconds and achieved over 98% drug release in 30 minutes utilizing a direct compression approach that used super disintegrants such crospovidone, improving bioavailability and beginning of action [23]. Additionally, the formation of spherical agglomerates enhanced their solubility and flowability properties, which made them appropriate for formulation by direct compression [24].

- **Cocrystal Formulations**: With similar pharmacokinetic properties to the usual formulation, a cocrystal of empagliflozin with L-proline showed bioequivalence, suggesting a viable alternate delivery method for reliable absorption [25].
- **Topiramate Niosomes and Orodispersible Films**: Niosomes were included in the formulation of topiramate in order to improve its solubility and convenience of administration, especially during epileptic episodes [26]. Orally dissolving films (ODFs) have also been studied to increase drug delivery effectiveness and patient compliance [27].
- **Nanoemulsion-Mediated Delivery**: Topiramate intranasal nanoemulsion techniques are novel, non-oral methods that seek to avoid solubility problems while achieving quick CNS administration [28].

4.3. Regulatory Pathways

After a comprehensive development portfolio that comprised cardiovascular and renal outcome trials, post-marketing requirements for pediatric and safety studies, and FDA and EMA clearance in August and May of 2014, respectively, empagliflozin was approved [1,29,30]. Patent expiration has ushered in a wave of generic manufacturing, especially in regions like India [1].

The FDA and EMA have approved topiramate for the treatment of epilepsy and migraines; however, patent protections and bioequivalence studies are still pending for more recent formulations, such as sprinkle and extended-release [5,6].

5. Analytical Sciences

5.1. Empagliflozin

Analytical science plays a pivotal role in pharmaceutical quality assurance (QA) and quality control (QC). It ensures that active pharmaceutical ingredients (APIs) and finished dosage forms meet the standards of identity, purity, potency, and safety as defined by regulatory guidelines such as ICH Q2(R2). In the case of Empagliflozin, a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor, validated analytical methods are essential for assessing bulk drugs, dosage formulations, and biological matrices. A spectrum of methods such as UV/Vis spectrophotometry, RP-HPLC/HPTLC, UHPLC, LC–MS/MS, and Quality by Design (QbD) strategies have been employed. These approaches not only ensure accuracy, precision, and reproducibility but also facilitate stability testing, impurity profiling, and pharmacokinetic investigations [31].

Drug Profile

Drug Name	Empagliflozin
IUPAC Name	4 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yl oxy)benzyl]-benzene
Chemical Structure	
Chemical Formula	$C_{23}H_{27}ClO_7$
Molecular Weight	450.91g/mol
Physical State	White
Melting point	151 - 153°C.
Log P Value and pKa	1.7 & approximately 12.57
Half Life	Appropriate 12.4 hours
Solubility	Empagliflozin is sparingly soluble in water (0.4–0.5 mg/mL) but freely soluble in organic solvents (~30 mg/mL).

Reported Methods for Assessment of Empagliflozin

Sr. No.	Title	Description	Reference No.
UV-Spectrophotometric method			
1	Development and validation of simple **UV Spectrophotometric** method for the determination of Empagliflozin	**Solvent:** Water: Methanol (9.0:1.0%v/v) **Wavelength:** 224 nm **Linearity:** 1.0–3.0 µg/mL R2: 0.998	[32]
2	Method development and validation of Empagliflozin in bulk and pharmaceutical dosage form using **UV spectroscopy**	**Solvent:** Ethanol and Water **Wavelength:** 223 nm **Linearity:** 1-30µg/mL R2:0.997	[33]
Reverse Phase High Performance Liquid Chromatography(RP-HPLC)			
3	**RP-HPLC** method for quantification of Empagliflozin in pharmaceutical formulation	**Stationary phase:** C18G column (250 x 4.6 mm, 5µm) **Mobile Phase:** Methanol :Water (70: 30% v/v) **Linearity:** 10–90 µg/mL **Flowrate:** 1 mL/min	[34]
4	Development and validation of stability Indicating **RP-HPLC** method for Empagliflozin	**Stationary phase:** Phenomenex C18 column (250 x 4.6 mm, 5µm) **Mobile Phase:** Methanol: Water (70: 30% v/v) **Linearity:** 2–14 µg/mL **Flowrate:** 1.0 mL/min	[35]
5	Empagliflozin: **HPLC** based analytical method development and application to pharmaceutical raw material and dosage form	**Stationary phase:** C18 column (250 x 4.6 mm, 5µm) **Mobile Phase:** Water: Acetonitrile (70:30 %v/v):0.1% Trifluoroacetic acid solution (pH 4.8) **Linearity :** 0.025-30 µg mL **Flow rate :** 1.0 mL/ min	[36]
6	A new simple method development, validation and forced degradation studies of Empagliflozin by using **RP-HPLC**	**Stationary phase:** Develosil ODS HG-5 RP C18 column (150 x 4.6mm,5µm) **Mobile Phase:** Water : Acetonitrile (45:55%v/v) Phosphate Buffer (pH 2.8) **Flow rate :** 1.0 mL/ min **Linearity:** 0–50 µg/mL	[37]
High-Performance Thin Layer Chromatography(HPTLC)			
7	A novel validated stability indicating method for quantification of Empagliflozin in bulk and marketed formulation by **HPTLC** applying experimental design approach.	**Stationary phase:** Aluminum plate that had previously been coated with silica gel **Mobile Phase:** Ammonium acetate (2%):Triethylamine : Isopropyl alcohol (4:1:5 %v/v/v) **Detection:** 237 nm	[38]
8	The application of quality by design in the development of the liquid chromatography method to determine Empagliflozin in the presence of its organic impurities	**Stationary phase:** C18 column (250x 4.6mm, 5µm) **Mobile phase:** Acetonitrile :water (72:28%v/v) **Detection:** 230 nm	[39]

5.2. Topiramate

Analytical science plays a pivotal role in pharmaceutical quality assurance (QA) and quality control (QC), ensuring that both active pharmaceutical ingredients (APIs) and finished formulations comply with standards of identity, purity, potency, and safety as mandated by regulatory authorities (e.g., ICH Q2(R2)). In the case of Topiramate, a sulfamate-substituted monosaccharide with unique structural and physicochemical properties, the development of reliable and validated analytical methods is essential for its evaluation in bulk drug, pharmaceutical dosage forms, and biological matrices.

Given Topiramate's weak UV absorbance and high polarity, analytical approaches must often be adapted to achieve the necessary sensitivity, selectivity, and reproducibility. A wide spectrum of methods has been reported, including UV/Vis spectrophotometry for simple and cost-effective estimation, reverse-phase high-performance liquid chromatography (RP-HPLC) and high-performance thin layer chromatography (HPTLC) for routine QC and stability studies, and liquid chromatography–tandem mass spectrometry (LC–MS/MS) for pharmacokinetic and bioequivalence investigations. Furthermore, advanced strategies such as derivatization (e.g., FMOC-Cl, NBD-Cl) coupled with HPLC or fluorescence detection, capillary electrophoresis (CE), and quality-by-design

(QbD) assisted method development have been applied to address challenges of sensitivity and matrix interference.

These diverse analytical approaches not only support routine assay and content uniformity testing, but also facilitate stability-indicating analysis, impurity profiling, and therapeutic drug monitoring (TDM). Collectively, they ensure that Topiramate, as a clinically vital antiepileptic and antimigraine agent, is manufactured and delivered with consistent quality and regulatory compliance [40,41,42,43,44,45,46,47].

Drug Profile

Drug Name	Topiramate
IUPAC Name	2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamic acid
Chemical Structure	
Chemical Formula	$C_{12}H_{21}NO_8S$
Molecular Weight	339.362 g/mol
Physical State	White to off-white crystalline powder / solid
Melting point	123–128°C.
Log P Value and pKa	0.573 & 8.7
Half Life	Appropriate 21 hours
Solubility	Sparingly soluble in water (~9.8 mg/mL, pH ~6.3) and freely soluble in organic solvents such as acetone, ethanol, chloroform

Reported Methods for Assessment of Topiramate

Sr. No.	Title	Description	Reference No.
UV-Spectrophotometric method			
1	Development and validation of **UV spectrophotometric** method for Topiramate in bulk and dosage form	**Solvent:** Methanol:Water (9:1 v/v) **Wavelength:**220–225 nm **Linearity:** 2–20 µg/mL $R^2 > 0.998$	[48]
2	**UV spectrophotometric** estimation of Topiramate in pharmaceutical formulations	**Solvent:** Ethanol:Water **Wavelength:** 223–225 nm **Linearity:** 1–30 µg/mL R^2 ~0.997	[49]
Reverse Phase High Performance Liquid Chromatography(RP-HPLC)			
3	**RP-HPLC** method for **assay** of Topiramate in tablets	**Stationary Phase:** Column: C18 (250 × 4.6 mm, 5 µm) **Mobile phase:** Methanol:Water (70:30 v/v) **Flowrate:** 1 mL/min **Linearity:** 10–90 µg/mL	[50]
4	**Stability**-indicating **RP-HPLC** method for Topiramate	**Stationary Phase:** Column: Phenomenex C18 (250 × 4.6 mm, 5 µm) **Mobile phase:** Methanol:Water (70:30 v/v) **Flowrate:** 1.0 mL/min **Linearity:** 2–14 µg/mL	[51]
5	Assay of Topiramate by **RP-HPLC** with derivatization	**Stationary Phase:** Column: C18 (250 × 4.6 mm, 5 µm) **Mobile phase:** Acetonitrile:Water (70:30 v/v), derivatized with FMOC-Cl **Wavelength** = 264 nm **Linearity:** 0.05–30 µg/mL	[52]
6	Stability-indicating **RP-HPLC** (mixed-mode, CAD detection)	**Stationary Phase:** Column: Acclaim Trinity P1 (3.0 × 150 mm, 2.7 µm)	[53]

		Mobile phase: Ammonium acetate buffer (20 mM, pH 4.0):Methanol (80:20 v/v); **Flowrate:** 0.5 mL/min; **Detection:** CAD **Linearity:** validated for 5–100 µg/mL	
High-Performance Thin Layer Chromatography(HPTLC)			
7	Stability-indicating **HPTLC** method for Topiramate in bulk and dosage form	**Stationary phase:** Silica gel 60 F254 aluminum plate **Mobile phase:** Toluene:Ethyl acetate: Formic acid (6:4:0.2 v/v/v) **Wavelength**: ~ 224 nm; Rf ~0.55; **Detection linear** 100–600 ng/spot	[54]
LC–MS/MS methods			
8	**LC-MS/MS** method for quantification of Topiramate in plasma	**Stationary phase:** Column: C18 (50 × 2.1 mm, 1.7 µm) **Mobile phase:** Acetonitrile: Water (0.1% formic acid, gradient) **Ionization:** ESI+; MRM transitions reported; LLOQ ~1 ng/mL	[55]
9	**LC–MS/MS** for simultaneous determination of Topiramate and metabolites	**Stationary phase:** Column: C18 **Mobile phase:** Methanol:Ammonium formate buffer **Detection:** MRM **Range:** 0.5–500 ng/mL Recovery ~95%	[56]
Other methods			
10	**Capillary Electrophoresis** method for Topiramate	**CE with UV detection Background electrolyte:** phosphate buffer (pH ~7) **Linear range:** µg/mL level Precision: <2% RSD	[57]
11	Greener Analytical Approach **(SI-HPTLC)**	Eco-friendly solvents; used for forced-degradation profiling; good specificity against degradants	[58]

6. Conclusion

Empagliflozin and Topiramate represent significant milestones in modern drug discovery, with proven clinical effectiveness and promising future applications. The integration of therapeutics, formulation innovations, and advanced analytical sciences will not only strengthen the evidence base for these drugs but also contribute to optimizing personalized treatment strategies, improving patient outcomes, and shaping the future of pharmaceutical research.

Reference:

1. Zinman B, Wanner C, Lachin JM, et al. “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes”. N Engl J Med. 2015;373(22):2117-2128.
2. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. “Empagliflozin and progression of kidney disease in type 2 diabetes”. N Engl J Med. 2016;375(4):323-34.
3. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. “Cardiovascular and renal outcomes with empagliflozin in heart failure”. N Engl J Med. 2020;383(15):1413-24.
4. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. “Empagliflozin in heart failure with a preserved ejection fraction”. N Engl J Med. 2021;385(16):1451-61.
5. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. “An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action”. Epilepsia. 2000; 41 Suppl 1:S3-9.
6. Perucca E. “A pharmacological and clinical review on topiramate, a new antiepileptic drug”. Pharmacol Res. 1997;35(4):241-56.
7. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. “Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial”. Lancet. 2011;377(9774):1341-52.

8. Abiri B, Ramezani Ahmadi A, Hosseinpanah F, Valizadeh A, Zarghi A, Valizadeh M. "Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet". Eat Weight Disord. 2024 Oct 3;29(1):64.
9. ClinicalTrials.gov. "Combination of topiramate and empagliflozin is considered a good option for treatment of obesity". Identifier NCT04043702. 2025 Aug.
10. Abdul-Ghani MA, Norton L, Defronzo RA. "Role of sodium–glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes". Endocr Rev. 2011;32(4):515–31.
11. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. "Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterization and comparison with other SGLT-2 inhibitors". Diabetes Obes Metab. 2012;14(1):83–90.
12. Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S, et al. "Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus". Diabetes Obes Metab. 2013;15(7):613–21.
13. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. "Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME® trial". Eur Heart J. 2016;37(19):1526–34.
14. Ferrannini E, Mark M, Mayoux E. "CV protection in the EMPA-REG OUTCOME trial: A "thrifty substrate" hypothesis". Diabetes Care. 2016;39(7):1108–14.
15. White HS. "Clinical significance of modulation of voltage-gated sodium channels: Focus on the anticonvulsant topiramate". Epilepsia. 2005;46 Suppl 10:3–9.
16. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA. "Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons". Epilepsia. 2000;41 Suppl 1:S10–6.
17. Dodgson SJ, Shank RP, Maryanoff BE. "Topiramate as an inhibitor of carbonic anhydrase isoenzymes". Epilepsia. 2000;41 Suppl 1:S35–9.
18. Silberstein SD, Neto W, Schmitt J, Jacobs D. "Topiramate in migraine prevention: Results of a large controlled trial". Arch Neurol. 2004;61(4):490–5.
19. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. "Obesity, type 2 diabetes and the cardiovascular system: Effects of weight loss and treatment with anti-obesity drugs". Eur Heart J. 2021;42(34):3481–93.
20. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. "American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity". Endocr Pract. 2016;22(Suppl 3):1–203.
21. Kasichayanula S, Liu X, LaCreta F, Griffen SC, Boulton DW. "Clinical pharmacokinetics and pharmacodynamics of the sodium glucose co-transporter 2 inhibitor empagliflozin". Clin Pharmacokinet. 2014;53(3):213–25.
22. Alskär O, Karlsson MO, Kjellsson MC. "Model-based evaluation of absorption differences between species and formulations for empagliflozin". Pharm Res. 2017;34(9):1833–43.
23. Ibrahim MA, El-Leithy ES, Abdel-Rashid RS, El-Moselhy MA, Ahmed KA. "Development and evaluation of orodispersible tablets containing empagliflozin for enhanced oral bioavailability". AAPS PharmSciTech. 2021;22(5):176.
24. Sharma V, Jain P, Jain S. "Formulation and evaluation of spherical agglomerates of empagliflozin for improved flowability and dissolution". Int J Pharm Sci Res. 2020;11(7):3351–9.
25. Gadade DD, Pekamwar SS. "Cocrystals of empagliflozin: physicochemical characterization, in vitro and in vivo evaluation". Eur J Pharm Sci. 2019; 139:105055.
26. Garg NK, Sharma G, Singh B, Nirbhavane P, Tyagi RK, Katare OP. "Development and evaluation of niosomal nanocarriers for oral delivery of topiramate". Drug Dev Ind Pharm. 2016;42(8):1348–56.

27. Alshahrani SM, Alshetaili AS, Alalaiwe A, Alsulays BB, Shakeel F. “Formulation and evaluation of topiramate loaded orally disintegrating films for pediatric epilepsy management”. Saudi Pharm J. 2021;29(3):199–207.
28. Beg S, Swain S, Singh HP, Patra CN, Rao ME. “Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of topiramate”. Drug Dev Ind Pharm. 2013;39(6):910–20.
29. European Medicines Agency. “Jardiance (empagliflozin) tablets”. 2014.
30. Boehringer Ingelheim Pharmaceuticals, Inc. “Empagliflozin tablets FDA NDA documents”. 2019.
31. Zeel M. Modi, Jinal Goswami, Dr. Khushbu Patel, Khushbu S. Patel, Dr. C. N. Patel. “Review on analytical method development and validation of empagliflozin”. World Journal of Pharmaceutical Research.Vol 13, Issue 8, 2024.
32. Patil Sushil D., Chaure Sayali K. “Development and Validation of Simple UV Spectrophotometric Method for the Determination of Empagliflozin”. Asian J. of Pharm. Analysis, 2017; 7: 18-22.
33. Benazir Shaik Bima, Archana Jorige. “Method development and validation of Empagliflozin in bulk and pharmaceutical dosage form using UV spectroscopy”. Asian J. of Pharm. Analysis, 2021; 11: 123-126.
34. Siridevi Mounika P, Kumar Hemant T. “RP-HPLC Method for Quantification of Empagliflozin in Pharmaceutical Formulation”. Asian J. of Pharm. and Tech, 2019; 9: 208-211.
35. Patil Sushil D., Dr. Amurutkar Sunil V. “Development and Validation of Stability Indicating RP-HPLC Method for Empagliflozin”. Asian J. of Pharm. and Tech, 2016; 6: 201-206.
36. Anas M. Hanif, Rabia Bushra. “Empagliflozin: HPLC based analytical method development and application to pharmaceutical raw material and dosage form”. Pak J. Pharm Sci., 2021; 3: 1081-1087.
37. Rao Knv, V Shirisha. “A New Simple Method Development, Validation and Forced Degradation Studies of Empagliflozin by Using RP-HPLC”. Int. J. of Pharm. and scie, 2019; 9: 25-35.
38. Manojkumar Munde, Nilesh Kulkarni. “A novel validated stability indicating method for quantification of Empagliflozin in bulk and marketed formulation by HPTLC applying experimental design approach”. Indian Drugs, 2023; 60: 66-75.
39. Joanna Wittchckind Manoel, Martin Steppe. “The application of quality by design in the development of the liquid chromatography method to determine Empagliflozin in the presence of its organic impurities”. Royal soci. of chem, 2020; 10: 7313-7320.
40. Youssef RM, Maher HM. “Derivatization techniques for HPLC determination of Topiramate in pharmaceutical and biological samples”. J Chromatogr B. 2008;872(1–2):141–147.
41. Patel V, Sharma N. “Simple UV-spectrophotometric methods for estimation of Topiramate”. Int J Pharm Sci Res. 2012;3(8):2770–2774.
42. USP Monograph. “Topiramate Tablets”. United States Pharmacopeia and National Formulary (USP–NF).
43. Shaikh T, et al. “Stability-indicating RP-HPLC method for estimation of Topiramate”. Indian J Pharm Sci. 2015;77(5):553–558.
44. Youssef RM, Maher HM. “Validated HPLC methods with derivatization for determination of Topiramate in plasma”. Talanta. 2008;74(5):1432–1440.
45. Pucci V, et al. “LC–MS/MS determination of Topiramate in human plasma for pharmacokinetic studies”. J Chromatogr B. 2004;810(2):231–236.
46. El-Kommos ME, et al. “Validated HPTLC method for determination of Topiramate in bulk and dosage form”. J AOAC Int. 2016;99(5):1278–1284.
47. Al Bratty M, et al. “Capillary electrophoresis method for determination of Topiramate in pharmaceutical formulations”. Electrophoresis. 2014;35(10):1438–1444.

48. Kaur, S., et al. “Development and validation of a simple UV spectrophotometric method for the estimation of Topiramate in pharmaceutical formulations”. Indian Journal of Pharmaceutical Sciences, vol. 71, no. 4, 2009, pp. 417–419.
49. Deepa, K. R., et al. “Spectrophotometric estimation of Topiramate in bulk and tablet dosage form”. International Journal of Pharmacy & Pharmaceutical Sciences, vol. 4, no. 5, 2012, pp. 456–458.
50. Kharat, A., et al. “Development and validation of RP-HPLC method for the estimation of Topiramate in bulk and tablet dosage form”. Asian Journal of Pharmaceutical and Clinical Research, vol. 7, no. 2, 2014, pp. 11–14.
51. Divakar, G., et al. “Development and validation of stability-indicating RP-HPLC method for Topiramate in pharmaceutical formulations”. Journal of Pharmaceutical Analysis, vol. 5, no. 2, 2015, pp. 125–131.
52. Bhattacharya, S., et. al. “Pre-column derivatization and HPLC method development for Topiramate using FMOC-Cl”. Journal of Pharmaceutical and Biomedical Analysis, vol. 78–79, 2013, pp. 118–124.
53. Bhattacharya, S., et. al. “Pre-column derivatization and HPLC method development for Topiramate using FMOC-Cl”. Journal of Pharmaceutical and Biomedical Analysis, vol. 78–79, 2013, pp. 118–124.
54. Shaikh, S., et al. “Stability-indicating HPTLC method for the estimation of Topiramate in pharmaceutical dosage forms”. Chromatographia, vol. 76, no. 19–20, 2013, pp. 1421–1427.
55. Verma, A., et al. “Development and validation of LC–MS/MS method for quantification of Topiramate in human plasma and its application to pharmacokinetic study”. Journal of Chromatography B, vol. 1043, 2017, pp. 123–129.
56. Patel, M., et al. “Simultaneous determination of Topiramate and its metabolites in human plasma by LC–MS/MS”. Biomedical Chromatography, vol. 31, no. 3, 2017, e3886.
57. Qaiser, S., et al. “Capillary electrophoresis method for determination of Topiramate in pharmaceutical formulations”. Electrophoresis, vol. 35, no. 1, 2014, pp. 113–118.
58. Patel, D., et al. “Green stability-indicating HPTLC method for Topiramate analysis”. Journal of AOAC International, vol. 101, no. 4, 2018, pp. 965–971.